Ace inhibitors and erythropoietin responsiveness.
Macdougall
I C
IC
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D016022:Case-Control Studies; D004347:Drug Interactions; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000008:administration & dosage*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000187:drug effects / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000378:metabolism / Q000628:therapy; D009842:Oligopeptides / Q000097:blood* / Q000378:metabolism; D011994:Recombinant Proteins
D000806:Angiotensin-Converting Enzyme Inhibitors; D009842:Oligopeptides; D011994:Recombinant Proteins; D004921:Erythropoietin; D007334:Insulin-Like Growth Factor I; C058504:goralatide